Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study.

Lombardi P, Kim JS, Manfredi GF, Celsa C, Fulgenzi CAM, D'Alessio A, Stefanini B, Doshi NC, Warmington E, Marron TU, Pinter M, Scheiner B, Kang B, Lim HY, Hsu WF, Wietharn B, Silletta M, Parisi A, Lin CY, Dalbeni A, Masi G, Schönlein M, von Felden J, Piscaglia F, Galle PR, Kudo M, Pressiani T, Rimassa L, Pirisi M, Cabibbo G, Chon HJ, Pinato DJ

Open source

DOI: 10.1016/j.jhepr.2025.101595
Published: 2025 Dec
Container: JHEP reports : innovation in hepatology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jhepr.2025.101595,
  title = {Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study.},
  author = {Lombardi P and Kim JS and Manfredi GF and Celsa C and Fulgenzi CAM and D'Alessio A and Stefanini B and Doshi NC and Warmington E and Marron TU and Pinter M and Scheiner B and Kang B and Lim HY and Hsu WF and Wietharn B and Silletta M and Parisi A and Lin CY and Dalbeni A and Masi G and Schönlein M and von Felden J and Piscaglia F and Galle PR and Kudo M and Pressiani T and Rimassa L and Pirisi M and Cabibbo G and Chon HJ and Pinato DJ},
  year = {2025},
  journal = {JHEP reports : innovation in hepatology},
  doi = {10.1016/j.jhepr.2025.101595},
  url = {https://doi.org/10.1016/j.jhepr.2025.101595}
}

RIS

TY  - JOUR
TI  - Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study.
AU  - Lombardi P
AU  - Kim JS
AU  - Manfredi GF
AU  - Celsa C
AU  - Fulgenzi CAM
AU  - D'Alessio A
AU  - Stefanini B
AU  - Doshi NC
AU  - Warmington E
AU  - Marron TU
AU  - Pinter M
AU  - Scheiner B
AU  - Kang B
AU  - Lim HY
AU  - Hsu WF
AU  - Wietharn B
AU  - Silletta M
AU  - Parisi A
AU  - Lin CY
AU  - Dalbeni A
AU  - Masi G
AU  - Schönlein M
AU  - von Felden J
AU  - Piscaglia F
AU  - Galle PR
AU  - Kudo M
AU  - Pressiani T
AU  - Rimassa L
AU  - Pirisi M
AU  - Cabibbo G
AU  - Chon HJ
AU  - Pinato DJ
PY  - 2025
JO  - JHEP reports : innovation in hepatology
DO  - 10.1016/j.jhepr.2025.101595
UR  - https://doi.org/10.1016/j.jhepr.2025.101595
ER  -

APA

P, L., JS, K., GF, M., C, C., CAM, F., A, D., B, S., NC, D., E, W., TU, M., M, P., B, S., B, K., HY, L., WF, H., B, W., M, S., A, P., CY, L., A, D., G, M., M, S., J, V. F., F, P., PR, G., M, K., T, P., L, R., M, P., G, C., HJ, C., & DJ, P. (2025). Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study.. JHEP reports : innovation in hepatology. https://doi.org/10.1016/j.jhepr.2025.101595

Source records

pubmed · retrieved 2026-09-25T08:50:27.115Z